3 Things In Biotech, June 3: CAR-T Cell Therapy Revs Up Again – Seeking Alpha
Seeking Alpha |
3 Things In Biotech, June 3: CAR–T Cell Therapy Revs Up Again
Seeking Alpha News: Legend Biotech announced that the FDA has allowed JNJ's Janssen to commence with a phase 1b/2 study involving its developmental CAR–T cell therapy called LCAR-B38M. This trial will enroll patients with relapsed or refractory multiple myeloma. |
